The Centers for Medicare & Medicaid Services has announced the selection of 15 prescription drugs for the third cycle of the Medicare Drug Price Negotiation Program. These are high-cost drugs covered under Medicare Part D and, for the first time, drugs payable under Medicare Part B.

The Trump administration on Tuesday announced the 15 drugs selected to participate in the newest round of the Medicare Drug Price Negotiation Program, including the high-cost medications Botox and Trulicity.